Orchestra BioMed Holdings OBIO
NASDAQ OBIO
$5.08 +0.34 (+7.17%)
At close: Sep 4, 2026 · 4:00 PM EDT

Orchestra BioMed Holdings (OBIO) Revenue Growth (1y) (2023 - 2026)

Analysis

Orchestra BioMed Holdings (OBIO) Revenue Growth (1y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 12.45%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 16.73%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 59.71%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 2.11%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 29.63%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 66.86%
8 Royalty Pharma 28.45 Bn 27.61 Bn - 16.50%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 296.11%
10 Orchestra BioMed Holdings 322.25 Mn 127.72 Mn 63,000.00 -89.47%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -89.47%
Mar 31, 2026 -87.33%
Dec 31, 2025 12,120.16%
Sep 30, 2025 -12.77%
Jun 30, 2025 7.46%
Mar 31, 2025 40.00%
Dec 31, 2024 -3.44%
Sep 30, 2024 135.56%
Jun 30, 2024 -14.97%
Mar 31, 2024 -46.74%
Dec 31, 2023 -76.25%
Sep 30, 2023 -63.97%
Jun 30, 2023 128.18%
Mar 31, 2023 34.41%